Interviews

Lyudmila A. Bazhenova, MD, discusses targeted therapies for patients with MET-mutated non–small cell lung cancer.

Aparna Hegde, MD, discusses the decision to use osimertinib as soon as possible in patients with EGFR-positive non–small cell lung cancer.

Tycel Phillips, MD, discusses the need for more effective agents for treating patients with relapsed/refractory mantle cell lymphoma as alternatives to chimeric antigen receptor T-cell therapy.

Danny Nguyen, MD, discusses next steps for research of mobocertinib in patients with EGFR-positive non–small cell lung cancer.

Paul G. Richardson, MD, discusses the latest regulatory movement in the multiple myeloma space.

Adam Cohen, MD, discusses his presentation on updates in BCMA-directed therapies for multiple myeloma, which he gave during the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

Guenther Koehne, MD, PhD, discusses the exciting presentations going on at the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

Samuel J. Klempner, MD, discusses unmet needs in patients with gastroesophageal adenocarcinoma when it comes to biomarker-targeted agents.

Srdan Verstovsek, MD, PhD, discusses the tolerability of pacritinib for patients with myelofibrosis.

Ravi Salgia, MD, explains how treatment with a tyrosine kinase inhibitor in patients with non–small cell lung cancer can lead to disease transformation.

Ronald L. Paquette, MD, discusses the selection of graft source for bone marrow and stem cell transplants in patients with myelodysplastic syndrome.

Nilanjan Ghosh, MD, PhD, discusses when a Bruton’s tyrosine kinase inhibitor would be preferred over a BCL-2 inhibitor as first-line therapy for patients with chronic lymphocytic leukemia.

Eric Nadler, MD, MPP, discusses the design and goals of a retrospective study of real-world adoption of atezolizumab immunotherapy in extensive-stage small cell lung cancer.

Lee Schwartzberg, MD, discusses important questions that have been raised due to the positive results of pembrolizumab immunotherapy for patients with triple-negative breast cancer.

Tycel Phillips, MD, discusses the potential use of glofitamab as therapy for patients with relapsed/refractory mantle cell lymphoma.

Lyudmila Bazhenova, MD, discusses targeted therapies for patients with KRAS-mutated non–small cell lung cancer.

Afshin Dowlati, MD, discusses treatment decision-making for patients with late-stage small cell lung cancer.

Bhavana Pothuri, MD, discusses ongoing and potential studies of copy-number low and high subgroups of patients with endometrial cancer.

Afshin Dowlati, MD, discusses the targeted therapies available for patients with EGFR-mutated late-stage non–small cell lung cancer.

Richard D. Carvajal, MD, discusses the mechanism of action and efficacy of tebentafusp-tebn for patients with uveal melanoma.

Ajay Chari, MD, discusses new blood testing options for patients with multiple myeloma.

Daniel P. Petrylak, MD, discusses the targeted therapies that have shown encouraging results in patients with metastatic urothelial cancer.

Ryan Sugarman, MD, discusses the design and purpose of the CheckMate 649 trial for gastroesophageal cancers, gastric cancer, and esophageal adenocarcinoma.

Sophia Kamran, MD, discusses the research supporting the use of trimodality therapy for patients with urothelial cancer.

Nitin Jain, MD, discusses the significance of a study of UCART22, an allogeneic chimeric antigen receptor T-cell therapy for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Ghaith Abu-Zeinah, MD, discusses the unmet needs investigational drugs could address for patients with polycythemia vera.

Tracy L. Rose, MD, MPH, discusses ongoing research in bladder cancer that aims to add onto the standard of care and improve patient outcomes.

Andrew Wei, MBBS, discusses characteristics associated with long-term survival in the QUAZAR AML-001 trial of oral azacitidine in patients with acute myeloid leukemia.

John Mascarenhas, MD, summarizes the treatment landscape for myelofibrosis, which now includes of pacritinib.

Naomi B. Haas, MD, discusses the use of VEGF tyrosine kinase inhibitors as neoadjuvant therapy for renal cell carcinoma.